Outcome of infants and young children with newly diagnosed ependymoma treated on the "head Start" III prospective clinical trial

Rajkumar Venkatramani, Lingyun Ji, Joseph Lasky, Kelley Haley, Alexander Judkins, Shengmei Zhou, Richard Sposto, Randal Olshefski, James Garvin, Tanya Tekautz, Gloria Kennedy, Shahrad Rod Rassekh, Theodore Moore, Sharon Gardner, Jeffrey Allen, Richard Shore, Christopher Moertel, Mark Atlas, Girish Dhall, Jonathan Finlay

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

This study investigates the outcome of children <10 years old with newly-diagnosed ependymoma treated on the prospective multinational "Head Start" III clinical trial. Between April 2004 and July 2009, 19 children with newly-diagnosed ependymoma were enrolled. All children were to receive five induction chemotherapy cycles followed by one consolidation cycle of myelo-ablative chemotherapy and autologous hematopoietic cell rescue. Children between 6 and 10 years of age or with residual tumor prior to consolidation were to receive irradiation thereafter. Median age of 19 children (8 female) was 20 months at diagnosis. Median follow up was 44 months. The primary site was infratentorial in 11 and supratentorial in 8 patients. Gross total resection was achieved in 10 patients. After induction chemotherapy, all three supratentorial ependymoma patients with residual disease achieved a complete response (CR), while only one of six infratentorial patients with residual disease achieved CR. Three infratentorial patients developed progressive disease during induction chemotherapy. All four infratentorial patients with residual disease who underwent autologous hematopoietic cell transplant, failed to achieve CR. Four patients received focal irradiation following chemotherapy. The 3-year event free survival (EFS) and overall survival (OS) for supratentorial ependymoma were 86 ± 13 % and 100 % respectively. The 3-year EFS and OS for infratentorial ependymoma were 27 ± 13 % and 73 ± 13 % respectively. The role of intensive induction and consolidation chemotherapy in deferring irradiation should be investigated further in children with supratentorial ependymoma with residual disease following surgery. This approach appears ineffective in children with infratentorial ependymoma in the absence of irradiation.

Original languageEnglish (US)
Pages (from-to)285-291
Number of pages7
JournalJournal of neuro-oncology
Volume113
Issue number2
DOIs
StatePublished - Jun 1 2013

    Fingerprint

Keywords

  • Ependymoma
  • Infratentorial
  • Irradiation
  • Supratentorial
  • Surgery

Cite this

Venkatramani, R., Ji, L., Lasky, J., Haley, K., Judkins, A., Zhou, S., Sposto, R., Olshefski, R., Garvin, J., Tekautz, T., Kennedy, G., Rassekh, S. R., Moore, T., Gardner, S., Allen, J., Shore, R., Moertel, C., Atlas, M., Dhall, G., & Finlay, J. (2013). Outcome of infants and young children with newly diagnosed ependymoma treated on the "head Start" III prospective clinical trial. Journal of neuro-oncology, 113(2), 285-291. https://doi.org/10.1007/s11060-013-1111-9